Compare Transocean Ltd (RIG) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Transocean Ltd vs Twist Bioscience Corp — how do they compare? Transocean Ltd trades at $5.56 (market cap $6.19B), while Twist Bioscience Corp trades at $159.5 (market cap $10.08B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Transocean Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Transocean Ltd for 18 Days and Twist Bioscience Corp for 27 Days on average.
| RIG | TWST | |
|---|---|---|
Market Cap | $6.19B | $10.08B |
Volume | 30,564,415 | 4,229,037 |
Sector | Energy | Health |
52-Week High | $7.58 | $205.00 |
52-Week Low | $3.08 | $25.45 |
Typical Hold Time | 18 Days | 27 Days |
Enterprise Value | $10.80B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Transocean (RIG) trades at $5.595, up 3.8% with bullish technical signals despite mixed earnings. The company shows strong revenue growth to $4.1B in 2026 but remains unprofitable with a -40.24% net margin. Recent $80M and $300M contract wins boost backlog, while the $5.8B Valaris acquisition advances after DOJ approval. Cash flow improved with $995M operating cash in 2026, supporting deleveraging efforts amid high debt levels.
RIG offers speculative upside through offshore cycle leverage and contract growth, but high debt and persistent losses pose significant risks. Analyst consensus is divided with 39% buy ratings, reflecting optimism about cash flow improvement versus concerns over profitability and execution risks from major acquisitions.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
